Source: Annual Congress 2006 - Clinical features of interstitial lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Radzikowska, E. Wiatr, R. Langfort, I. Bestry, K. Roszkowski (Warsaw, Poland). Clarithromycin in organizing pneumonia: a preliminary study. Eur Respir J 2006; 28: Suppl. 50, 1773

Member's Comments

No comment yet.

Related content which might interest you: Abstract organizing pneumonia: nationwide epidemiological study Source: Eur Respir J 2005; 26: Suppl. 49, 268s Year: 2005 Corticosteroids for community-acquired pneumonia: a critical view of the evidence Source: Eur Respir J 2016; 48: 984-986 Year: 2016 Etiology of community-acquired pneumonia: an autopsy study Source: Annual Congress 2006 - Miscellaneous respiratory infections I Year: 2006 Barriers to adherence to key indicators of antibiotic use for community-acquired pneumonia: a qualitative study Source: Eur Respir J 2005; 26: Suppl. 49, 258s Year: 2005 The extent of microbiological testing and antibiotic de-escalation in adults with community-acquired pneumonia: a retrospective cohort study. Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018 Management of community-acquired pneumonia in primary care: an observational study Source: International Congress 2019 – Treatment of airway diseases in primary care Year: 2019 Macrolides as a potential treatment in organizing pneumonia Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019 Cryptogenic organizing pneumonia – Results of treatment with clarithromycin versus corticosteroids Source: International Congress 2016 – Orphan diseases II Year: 2016 Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study Source: Eur Respir J 2015; 46: 1205-1207 Year: 2015 Pentraxin 3 in community-acquired pneumonia: A pilotal study Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools Year: 2010 Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study Source: ERJ Open Res, 4 (4) 00096-2018; 10.1183/23120541.00096-2018 Year: 2018 Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis Source: Eur Respir J 2008; 31: 1068-1076 Year: 2008 Etiology of community-acquired pneumonia requiring hospitalization in Chile: a prospective study Source: Eur Respir J 2005; 26: Suppl. 49, 255s Year: 2005 Costs of treatment of hospitalised community-acquired pneumonia from the hospitals’ perspective – a prospective study comparing moxifloxacin with other antibiotic treatment alternatives Source: Eur Respir J 2004; 24: Suppl. 48, 185s Year: 2004 Community-acquired pneumonia in the elderly: Spanish multicentre study Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001 Mortality directly related to community-acquired pneumonia (CAP) in hospitalized patients: results from the community-acquired pneumonia organization (CAPO) international cohort study Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Atypical bacterial and viral ethiology of community-acquired pneumonia in Chile: a preliminary report Source: Eur Respir J 2006; 28: Suppl. 50, 352s Year: 2006